Second-generation antisense drug ISIS 104838 reduces TNF-alpha in rheumatoid arthritis patients
Isis Pharmaceuticals highlights upcoming presentation of trial results At the 67th annual meeting of the American College of Rheumatology
22-Sep-2003 -
ISIS 104838 reduced TNF-alpha mRNA levels in synovial tissue and stabilized levels of TNF-alpha in blood, according to interim results of a Phase 2a clinical trial in rheumatoid arthritis (RA) patients receiving 300 mg of the second-generation antisense drug. Isis Pharmaceuticals, Inc. ...
biomarker
clinical trials
rheumatoid arthritis
+1